Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00109668 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Two Doses of QVAR Versus Placebo by Breath Operated and Metered Dose Inhalers in Moderate Asthmatic Adolescents and Adults on a Stable Regimen of Inhaled Corticosteroids
A Phase 3 study, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 3
- Development phase
- 415
- Enrollment target
NCT00109668 is a Phase 3 study that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 415 participants.
The verdict
NCT00109668, a Phase 3 study, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 415 participants
- Enrollment target
Study Summary
QVAR in a standard press and breath inhaler (QVAR-MDI) has been approved by the Food and Drug Administration (FDA) for use in the United States. The purpose of this study is to determine the level of asthma control when comparing the safety and effectiveness of QVAR in two different devices, a metered dose inhaler (MDI) and a breath operated inhaler (BOI).
Interventions
- DRUG beclomethasone dipropionate (QVAR)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 415 participants |
| Start Date | 2004-07-31 |
| Est. Completion | 2006-09-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00109668
The ClinicalTrials.gov registry entry for NCT00109668 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 415 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which beclomethasone dipropionate (QVAR) is the first listed.
NCT00109668 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00109668 about?
NCT00109668 is a clinical study titled "Evaluation of Two Doses of QVAR Versus Placebo by Breath Operated and Metered Dose Inhalers in Moderate Asthmatic Adolescents and Adults on a Stable Regimen of Inhaled Corticosteroids". QVAR in a standard press and breath inhaler (QVAR-MDI) has been approved by the Food and Drug Administration (FDA) for use in the United States. The purpose of this study is to determine the level of asthma control when comparing the safety and effectiveness of QVAR in two different devices, a meter...
What is the current status of trial NCT00109668?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 415 participants. The study started on 2004-07-31. Estimated completion is 2006-09-30.
What interventions are being tested in trial NCT00109668?
The interventions under investigation include: beclomethasone dipropionate (QVAR) (DRUG).
Who is sponsoring clinical trial NCT00109668?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.